Company intelligence / Profile preview

Jeil Chemical

Seoul, Seoul, South Koreajeilchemical.kr ↗

Ownership: Private
Development stage: Other

Overview

Jeil Pharmaceutical has a broad commercial portfolio including small molecules and biologics for various indications such as diabetes, oncology, cardiovascular disease, and gastrointestinal disorders. Its pipeline includes JPI‑289 in Phase II for myocardial infarction targeting PARP1. The company has achieved multiple product approvals in South Korea and internationally.

Therapeutic areas: OncologyEndocrinologyGastroenterologyCardiovascularInfectious Diseases
Modalities: Small moleculeBiologicPeptidesPatch-based drug delivery
Industry: Biotech

Partnerships

Takeda Korea co-promotion agreementsLundbeck Korea co-promotion agreementsR&D cooperation with Gyeonggi Institute of Science and TechnologyBaxter Korea co-promotion agreementYao Pharma in China (joint venture)

Beyond the preview

Go deeper on Jeil Chemical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jeil Chemical.

Explore the full profile